[go: up one dir, main page]

DK2012789T3 - Fremgangsmåde til behandling af aldersrelateret makulær degeneration (AMD) - Google Patents

Fremgangsmåde til behandling af aldersrelateret makulær degeneration (AMD)

Info

Publication number
DK2012789T3
DK2012789T3 DK07718737.5T DK07718737T DK2012789T3 DK 2012789 T3 DK2012789 T3 DK 2012789T3 DK 07718737 T DK07718737 T DK 07718737T DK 2012789 T3 DK2012789 T3 DK 2012789T3
Authority
DK
Denmark
Prior art keywords
amd
age
macular degeneration
related macular
degeneration
Prior art date
Application number
DK07718737.5T
Other languages
English (en)
Inventor
Ashley Bush
Colin Louis Masters
Penelope Jane Huggins
Jack Gordon Parsons
Gaik Beng Kok
Vijaya Kenche
Sous Mariana El
Original Assignee
Prana Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prana Biotechnology Ltd filed Critical Prana Biotechnology Ltd
Application granted granted Critical
Publication of DK2012789T3 publication Critical patent/DK2012789T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07718737.5T 2006-04-14 2007-04-13 Fremgangsmåde til behandling af aldersrelateret makulær degeneration (AMD) DK2012789T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79227806P 2006-04-14 2006-04-14
PCT/AU2007/000490 WO2007118276A1 (en) 2006-04-14 2007-04-13 Method of treatment of age-related macular degeneration(amd)

Publications (1)

Publication Number Publication Date
DK2012789T3 true DK2012789T3 (da) 2013-12-16

Family

ID=38608967

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07718737.5T DK2012789T3 (da) 2006-04-14 2007-04-13 Fremgangsmåde til behandling af aldersrelateret makulær degeneration (AMD)

Country Status (14)

Country Link
US (3) US20100144693A1 (da)
EP (2) EP2012789B1 (da)
JP (1) JP5290147B2 (da)
KR (2) KR20080109096A (da)
CN (3) CN101534826A (da)
AU (2) AU2007240120A1 (da)
BR (2) BRPI0710737A2 (da)
CA (1) CA2683756A1 (da)
DK (1) DK2012789T3 (da)
ES (1) ES2437997T3 (da)
IL (1) IL207495A (da)
NZ (2) NZ590271A (da)
WO (1) WO2007118276A1 (da)
ZA (2) ZA200809493B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
DK2044026T3 (da) * 2006-06-22 2014-06-30 Prana Biotechnology Ltd Fremgangsmde til behandling af cerebral glioma tumor
JP2011530596A (ja) * 2008-08-11 2011-12-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用
DK2379510T3 (da) * 2008-12-24 2016-12-19 Prana Biotechnology Ltd Quinazolinonforbindelser
MX2011007947A (es) 2009-01-26 2011-12-14 Joshua Lawrence Dunaief Relacionados con el hierro.
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2012122534A2 (en) 2011-03-10 2012-09-13 The Trustees Of Columbia University In The City Of New York N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
JP2015506363A (ja) 2012-01-13 2015-03-02 プレジデント アンド フェローズ オブ ハーバード カレッジ ハロフジノール誘導体、および化粧料組成物および医薬組成物におけるその使用
SG11201504859YA (en) 2012-12-20 2015-07-30 Aldeyra Therapeutics Inc Peri-carbinols
EP2948149A4 (en) 2013-01-23 2016-12-14 Aldeyra Therapeutics Inc BY TOXIC ALDEHYDIC DISEASES AND TREATMENT
SG11201505599YA (en) 2013-01-25 2015-08-28 Aldeyra Therapeutics Inc Novel traps in the treatment of macular degeneration
CA2968090A1 (en) * 2014-12-02 2016-06-09 Prana Biotechnology Limited 4h-pyrido[1,2-a]pyrimidin-4-one compounds
WO2016175585A1 (ko) * 2015-04-29 2016-11-03 주식회사 트리아펙스 편광 필름, 이의 제조 방법, 및 이를 포함하는 편광 렌즈
WO2017027064A1 (en) * 2015-08-12 2017-02-16 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
MX2018002155A (es) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Compuestos deuterados y usos de los mismos.
US11008290B2 (en) * 2015-09-24 2021-05-18 University Of Florida Research Foundation, Incorporated Halogenated quinoline derivatives as antimicrobial agents
MX2018013472A (es) 2016-05-09 2019-02-28 Aldeyra Therapeutics Inc Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
AU2017288056A1 (en) 2016-07-01 2019-01-17 Prana Biotechnology Limited Method of treating immunoglobulin light chain amyloidosis
CN110431130A (zh) 2017-03-16 2019-11-08 奥尔德拉医疗公司 多晶型化合物和其用途
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
CN109232396B (zh) * 2018-11-27 2020-07-03 聊城大学 酰胺吡啶类衍生物及其用途
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
AU2021300425A1 (en) * 2020-07-02 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclic compounds for use in treating retinal degeneration
US12060334B2 (en) 2021-03-12 2024-08-13 University Of Florida Research Foundation, Incorporated 3-substituted phenazine derivatives as antimicrobial agents
CN113214249B (zh) * 2021-04-23 2023-09-19 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE505711A (da) 1950-09-09
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
HU178910B (en) * 1977-08-19 1982-07-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IT1204612B (it) 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
EP0693150B1 (de) 1993-04-08 1996-08-28 Ideal-Standard Gmbh Sanitäres wasserventil
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DE4418096A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
SI0959888T1 (en) 1996-08-13 2002-10-31 P. N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
DE69922986T2 (de) 1998-10-22 2005-07-07 Neurosearch A/S Substituierte phenylderivate, ihre herstellung und verwendung
US6369058B1 (en) * 1999-02-04 2002-04-09 New Millennium Pharmaceutical Research Inc. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke
DE60031285T2 (de) 1999-08-27 2007-08-30 Chemocentryx Inc., Mountain View Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
CA2432222C (en) 2000-12-21 2008-07-29 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
FR2819187A1 (fr) 2001-01-10 2002-07-12 Michel Xilinas Utilisation des substances chelatrices pour le traitement et la prevention de la deferrescence oculaire
DE60231868D1 (de) 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
FR2827599A1 (fr) * 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
WO2003016309A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Process for preparing 5-sulfonamido-8-hydroxy-1, 6-naphthyridine-7-carboxamides
JP4470219B2 (ja) 2002-02-20 2010-06-02 味の素株式会社 新規フェニルアラニン誘導体
AU2003228283A1 (en) 2002-03-07 2003-09-22 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2002951868A0 (en) * 2002-10-04 2002-10-24 Prana Biotechnology Limited Compound i
CA2500952C (en) * 2002-10-04 2011-04-26 Prana Biotechnology Limited Neurologically-active compounds
AU2004226876A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
CA2529256A1 (en) * 2003-06-23 2004-12-29 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US8084459B2 (en) * 2004-04-02 2011-12-27 Prana Biotechnology Ltd Substituted quinazolinones for treating neurological conditions
AU2006211625A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2006117660A2 (en) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
DK2044026T3 (da) * 2006-06-22 2014-06-30 Prana Biotechnology Ltd Fremgangsmde til behandling af cerebral glioma tumor

Also Published As

Publication number Publication date
CN101534826A (zh) 2009-09-16
ES2437997T3 (es) 2014-01-15
US20140088122A1 (en) 2014-03-27
ZA201005922B (en) 2013-09-25
CN101987849A (zh) 2011-03-23
JP2009533356A (ja) 2009-09-17
EP2012789A1 (en) 2009-01-14
CN101987849B (zh) 2013-05-08
JP5290147B2 (ja) 2013-09-18
WO2007118276A1 (en) 2007-10-25
EP2012789A4 (en) 2011-02-16
BRPI0710737A2 (pt) 2011-05-10
CA2683756A1 (en) 2007-10-25
KR20100110396A (ko) 2010-10-12
IL207495A (en) 2015-05-31
US20110071167A1 (en) 2011-03-24
AU2010206074A1 (en) 2010-08-19
BRPI0722382A2 (pt) 2012-06-05
ZA200809493B (en) 2010-08-25
AU2010206074B2 (en) 2012-08-30
CN102225930A (zh) 2011-10-26
KR20080109096A (ko) 2008-12-16
NZ590271A (en) 2011-12-22
AU2007240120A2 (en) 2008-12-18
US20100144693A1 (en) 2010-06-10
IL207495A0 (en) 2010-12-30
EP2012789B1 (en) 2013-09-25
US9163018B2 (en) 2015-10-20
EP2514423A2 (en) 2012-10-24
AU2007240120A1 (en) 2007-10-25
NZ572591A (en) 2012-01-12
EP2514423A3 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
DK2012789T3 (da) Fremgangsmåde til behandling af aldersrelateret makulær degeneration (AMD)
DK2187880T3 (da) Sammensætninger og fremgangsmåder til behandling af makuladegeneration
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2046767T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2270118T3 (da) Fremgangsmåde til fremstilling af en carbonhydridkomponent
DK2044002T3 (da) Fremgangsmåde til fremstilling af 3-substituerede 2-amino-5-halobenzamider
DK2054711T3 (da) Fremgangsmåde til fremstilling af mikroarrays
DK2164831T3 (da) Fremgangsmåde til fremstilling af n-substituerede (3-dihalomethyl-1-methyl-pyrazol-4-yl)carboxamider
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
DK2029567T3 (da) Fremgangsmåde til frembringelse af benzopyran-2-ol-derivater
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK3605915T3 (da) Forbedret protokolsynkronisering til HARQ
DK2035166T3 (da) Fremgangsmåde til fremstilling af beholdere
DK2001312T3 (da) Fremgangsmåde til fremstilling af en protein-drik
DK2048941T3 (da) Fremgangsmåde til opdræt af rovmider
DK2061746T3 (da) Fremgangsmåde til fremstilling af diestere
DK2215031T3 (da) Fremgangsmåde til bearbejdning af pozzolaner
DK2007208T3 (da) Sterilisationsproces til fremstilling af en levnedsmiddelsammensætning
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
DK2865422T3 (da) Alpha-msh-derivater til behandling af fotodermatoser
DK2358661T3 (da) Fremgangsmåde til fremstilling af trans-4-amino-cyclohexyl-eddikesyreethylester-hcl
DK1961770T3 (da) Fremgangsmåde til fremstilling af et kompleks
DK2160225T3 (da) Fremgangsmåde til fremstilling af krystaller
DK2020845T3 (da) Fremgangsmåde til høstning
DK1856024T3 (da) Fremgangsmåde til fremstilling af substituerede biphenyler